Marvin Nguyen

This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.

Real-world data show most first-line mTNBC patients are immunotherapy-ineligible, use chemotherapy, and face poorer survival, underscoring major unmet treatment needs.

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

In a real-world cohort of 300 patients with HER2-low metastatic breast cancer, T-DXd demonstrated a safety profile consistent with DESTINY-Breast04 in community oncology settings, with ILD/pneumonitis in 10% and toxicity-related discontinuation in 15%.